

PIŚMIENNICTWO

1. Advokat C, Kutlesic V. Pharmacotherapy of the eating disorders: a commentary. *Neurosci Biobehav Rev* 1995; 19: 59-66.
2. Agras WS. Treatment of binge eating disorder. W: Gabbard GO (wyd.): *Treatments of psychiatric disorders* (3 rd ed.) Washington, DC, American Psychiatric Press 2001, 2209 – 2219.
3. Agras WS, Telch DF, Arnow B. Weight loss, cognitive – behavioral, and desipramine treatments in binge eating disorder. An additive design. *Behav Ther* 1004; 25: 225-238.
4. Allende LM, Corell A, Manzanares J, Madruga D i wsp. Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. *Immunology* 1998; 94 (4): 543- 551.
5. Alvin P, Zogheib J. Severe complications and mortality in mental eating disorders in adolescence. On 99 hospitalized patients. *Arch Fr Pediatr* 1993; 50 (9): 755-762.
6. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders* (4th ed.) TR, Washington, DC, APA 1994.
7. Anderson JW, Greenway FL, Fujioka K. Bupropion SR enhances weight loss: a 48 – week double – blind, placebo – controlled trial. *Obes Res* 2002; 10: 633-641.
8. Appolinario JC, Bacaltchuk J, Sichiari R. A randomized double-blind, placebo – controlled study of sibutramine in the treatment of binge eating disorder. *Arch Gen Psychiatry* 2003; 60: 1109-1116.
9. Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. *Curr Drug Targets* 2004; 5: 301-307.
10. Arnold LM, McElroy SL, Hudson JI, Welge JA i wsp. A placebo – controlled, randomized trial of fluoxetine in the treatment of binge – eating disorder. *J Clin Psychiatry* 2002; 63: 1028-1033.
11. Audi L, Vargas DM, Gussinye M, Yeste D, Carrascosa A. Clinical and biochemical determinants of bone metabolism and bone mass in adolescent female patients with anorexia nervosa. *Pediatr Res* 2002; 51: 1-8.
12. Backett SA. Acute pancreatitis and gastric dilatation in a patient with anorexia nervosa. *Postgrad Med J* 1985; 61 (711): 39-40.
13. Ballauff A, Ziegler A, Emons G. Serum leptin and gonadotropin levels in patients with anorexia nervosa during weight gain. *Mol Psychiatry* 1999; 4: 71-75.
14. Bessler H, Karp I, Notti L, Apter A, Tyano S i wsp. Cytokine production in anorexia nervosa. *Clin Neuropharmacol* 1993; 1 (6): 237-243.
15. Biederman J, Herzog DB, Rivinus TM, Harper GP i wsp. Amitriptyline in the treatment of anorexia nervosa: a double-blind placebo – controlled study. *J Clin Psychopharmacol* 1985; 5: 10-16.
16. Bonne OB, Bloch M, Berry EM. Adaptation to severe chronic hypokalemia in anorexia nervosa: a plea for conservative management. *Int J Eat Disord* 1993; 13 (1): 125-128.
17. Brabiuche MR, Levy-Soussan P. Anorexia nervosa and lower vulnerability to infections. *Am J Psychiatry* 1993; 150: 169-170.
18. Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive – behavioral, psychopharmacological and nutritional therapy in eating disorders 2. Anorexia nervosa – binge-eating/purging type. *Neuropsychobiology* 1995; 32: 64-67.
19. Brambilla F, Ferrari E, Brunetta M, Peirone A i wsp. Immunoenocrine aspects of anorexia nervosa. *Psychiatry Res* 1996; 16 (1): 97-104.
20. Branson R, Potoczna N, Kral JG. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. *N Engl J med* 2003; 348: 1096-1103.
21. Braun DL, Sunday SR, Halmi KA. Psychiatric comorbidity in patients with eating disorders. *Psychol Med* 1994; 24: 859.
22. Bray GA, Hollander P, Klein S. A 6-month randomized, placebo – controlled, dose – ranging trial of topiramate for weight loss in obesity. *Obes Res* 2003; 11: 722-733.
23. Carter WP, Hudson JI, Lalonde JK, Pindyck L I wsp. Pharmacological treatment of binge eating disorder. *Int Eat Disord* 2003; 34 Suppl: S 74- S88.
24. Casper RC. Personality features of women with good outcome from restricting anorexia nervosa. *Psychosom Med* 1990; 52:156.
25. Cooke RA, Chambers JB. Anorexia nervosa and the heart. *Br J Hosp Med* 1995; 54 (7), 313-317.
26. Cooke RA, Chambers JB, Singh R, Todd GJ, Smeeton NC, Treasure J, Treasure T. QT interval in anorexia nervosa. *Br Heart J* 1994; 72 (1): 69-73.
27. Crisp AH, Callender JS, Halek C i wsp. Long-term mortality in anorexia nervosa. A 20 year follow-up of the St. George's and Aberdeen cohorts. *Br J Psychiatry* 1992; 161:104-107.
28. Crisp AH, Palmer RL, Kaluchy RS. How common is anorexia nervosa? A prevalent study. *Br J Psychiatry* 1976; 128: 549.
29. Devlin MJ, Goldfein JA, Petkova E, Jiang H, Raizman PS i wsp. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. *Obes Res* 2005; 13: 1077-1088.
30. De Zwaan M. Binge eating disorder and obesity. *Int J Obes Relat metab Disord* 2001; 25 (suppl 1): 51-55.
31. Durakovic Z, Durakovic A, Korsic M. Changes of the corrected QT interval in the electrocardiogram of patients with anorexia nervosa. *Int J Cardiol* 1994; 45 (2): 115-120.
32. Eckert ED, Halmi KA, Marchi EP. Ten-year follow-up of anorexia nervosa: Clinical course and outcome. *Psychol Med*. 1995; 25: 143.
33. Fairburn CG i wsp. Cognitive – behavioural therapy for binge eating and bulimia nervosa; a comprehensive treatment manual. W: Fairburn CG, Wilson GT (red.) *Binge Eating: Nature, Assessment and Treatment*. New York: Guilford Press, 1993, 361-404.
34. Frank GK, Kaye WH, Marcus MD. Sertraline in underweight binge eating/purging – type eating disorders: five case reports. *Int J Eat Disord* 2001; 29: 495-498.
35. Gniuli D, Liverani E, Capristo E, Greco AV, Mingrone G. Blunted glucose metabolism in anorexia nervosa. *Metabolism* 2001; 50(8): 876-881.
36. Goldstein DJ, Wilson MG, Ascroft RC, al-Banna W. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. *Int J Eat Disord* 1999; 25: 19-27.
37. Gorwood P. Eating disorders, serotonin transporter polymorphisms and potential treatment response. *Am J Pharmacogenomics* 2004; 4: 9-17.
38. Grilo CM. A controlled study of cognitive behavioral therapy and fluoxetine in binge eating disorder. Charleston, SC: Eating Disorders Research Society, Annual Meeting of APA 2002.
39. Halmi KA, Eckert E, Marchi EP, Sampugnaro R, Apple R, Cohen J. Comorbidity of psychiatric diagnosis in anorexia nervosa. *Arch Gen Psychiatry* 1991; 48:712.
40. Hay PJ, Bacaltchuk J. Psychotherapy for bulimia nervosa and bingeing. *Cochrane Database Syst Rev* 2000; 4: CD000562.
41. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR i wsp. Treatment of bulimia nervosa with topiramate in a randomized, double – blind, placebo – controlled trial, part 1: improvement in binge and purge measures. *J Clin Psychiatry* 2003; 64: 1335-1341.
42. Hudson JI, Carter WP, Pope HG Jr. Antidepressants treatment of binge – eating disorder: research findings and clinical guidelines. *J Clin Psychiatry* 1996; 57 Suppl: 73-79.
43. Hudson JI, McElroy SL, Raymond NC, Crow S i wsp. Fluvoxamine in the treatment of binge – eating disorder: a multi-

- center placebo – controlled, double – blind study. *Am J Psychiatry* 1998; 155: 1756-1762.
44. Jagielska G, Wolańczyk T, Komender J, Tomaszewicz- Libudziec C, Przedlacki J, Ostrowski K. Bone mineral content and bone mineral density in adolescents girls with anorexia nervosa: a longitudinal study. *Acta Psychiatr Scand* 2001; 104: 131-37.
 45. Jagielska G, Tomaszewicz-Libudziec C, Brzozowska A, Komender J. Zaburzenia kardiologiczne u chorych na jadłowstręt psychiczny. *Psychiatr Pol* 2001; 35 (1): 81-91.
 46. Jimerson DC, Herzog DB, Brotman AW. Pharmacologic approaches in the treatment of eating disorders. *Harv Rev Psychiatry* 1993; 1: 82-93.
 47. Kaplan AS. Academy for Eating Disorders International Conference on Eating disorders. Denver, CO, USA, May 29-31, 2003. *Expert Opin Investig Drugs* 2003; 12: 1441-1443.
 48. Keel PK, Mitchell J, Miller K, Davis T, Crow S. Long term outcome of bulimia nervosa. *Arch Gen Psychiatry* 1999; 55: 63.
 49. Keel P, Dorer DJ, Eddy KT i wsp. Predictors of mortality in eating disorders. *Arch Gen Psychiatry* 2003; 60 (2): 179-183.
 50. Kollai M, Bonyhay I, Jokkel G, Szonyi L. Cardiac vagal hyperactivity in adolescent anorexia nervosa. *Eur Heart J* 1994; 15 (8): 1113-1118.
 51. Komender J, Popielarska A, Tomaszewicz-Libudziec E, Jagielska G i wsp. Odległe wyniki leczenia dorastających chorych na jadłowstręt psychiczny. *Psychiatr Pol* 1998; 32 (6): 759-769.
 52. Komorowska-Pietrzykowska R, Rajewski A, Sobieska M, Wiktorowicz K. Interleukin 6, tumor necrosis factor α and interferon γ in patients with anorexia nervosa. *Progres in Basic and Clinical Immunology*, Kluwer Academic/Plenum Publishers, New York, 2001.
 53. Korndörfer SR, Alexander RL, Sumon VJ i wsp. Long-term survival of patients with anorexia nervosa: a population based study in Rochester. *Minn. Mayo Clin Proc* 2003; 78: 278-284.
 54. Kruger S, Kennedy SH: Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge – eating disorder. *J Psychiatry Neurosci* 2000; 25: 497-508.
 55. Malhotra S, King KH, Welge JA, Brusman – Lovins L, McElroy SL: Venlafaxine treatment of binge – eating disorder associated with obesity: a series of 35 patients. *J Clin Psychiatry* 2001; 63: 802-806.
 56. Malhotra S, King KH, Welge JA. Venlafaxine treatment of binge – eating disorder associated with obesity: a series of 35 patients. *J Clin Psychiatry* 2002; 63: 802-806.
 57. Mayer LE, Walsh BT. The use of selective serotonin reuptake inhibitors in eating disorders. *J Clin Psychiatry* 1998; 59 Suppl: 28-34.
 58. Mc Elroy SL, Arnold LM, Shapira NA. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo controlled trial. *Am J Psychiatry* 2003; 160: 255-261.
 59. McElroy SL, Shapira NA, Arnold LM, Keck PE i wsp. Topiramate in the long – term treatment of binge – eating disorder associated with obesity. *J Clin Psychiatry* 2004; 65:1463-1469.
 60. McElroy SL, Hudson JI, Malhorta S, Welge JA i wsp. Citalopram in the treatment of binge eating disorder: a placebo controlled trial. *J Clin Psychiatry* 2003; 64: 807-813.
 61. McElroy SL, Kotwal R, Hudson JI. Zonisamide in the treatment of binge eating disorder; an open – label , prospective trial. *J Clin Psychiatry* 2004; 65: 50-56.
 62. Meyers DG, Starke H, Pearson PH, Wilken MK, Ferrell JR. Leaflet to left ventricular size disproportion and prolapse of a structurally normal mitral valve in anorexia nervosa. *Am J Cardiol* 1987; 60 (10): 911-914.
 63. Milano W, Petrella C, Casella A, Capasso A i wsp. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge – eating disorder: a placebo – controlled study. *Adv Ther* 2005; 22: 25-31.
 64. Milner EA, Cioffi WG, McManus WF, Pruitt BA Jr. Superior mesenteric artery syndrome in a burn patients. *Nutr Clin Pract* 1995; 8 (6): 264-266.
 65. Mitchell JE, Groat R. A placebo – controlled, double – blind trial of amitriptyline in bulimia. *J Clin Psychopharmacol* 1984; 4: 186-193.
 66. Mitchell JE, de Zwaan M, Roerig JL. Drug therapy for patients with eating disorders. *Curr Drug Targets CNS Neurol Disord* 2003; 2: 17-29.
 67. Mitchell JE, Tareen B, Sheehan W, Agras S i wsp. Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa. *Int Eat Disord* 2000; 28: 1-7.
 68. Mitchell JE, Gosnell BA, Roerig JL. Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. *Obes Res* 2003; 11: 599- 602.
 69. Möller-Madsen S, Nystrup J, Nielsen S. Mortality in anorexia nervosa in Denmark during the period 1970-1987. *Acta Psychiatr Scand* 1996; 94: 454-459.
 70. National Institute for Clinical Excellence. Clinical Guideline 9. Eating disorders. Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. National Collaborating Centre for Mental Health, January 2004.
 71. Ogston D, Ogston WD. The fibrinolytic enzyme system in anorexia nervosa. *Acta Haematol.* 1976; 55 (4): 230-233 .
 72. Oka Y, Ito T, Matsumoto S, Suematsu H, Ogata E. Mitral valve prolapse in patients with anorexia nervosa. Two – dimensional echocardiographic study. *Ipn Heart J* 1987; 28 (6): 973-882.
 73. Palmer RL. Death in anorexia nervosa. *Lancet* 2003; 361: 1490.
 74. Patton GC. Mortality in eating disorders. *Psychol Med* 1988; 18: 947-951.
 75. Pederson KJ, Roerig JL, Mitchell JE. Towards the pharmacotherapy of eating disorders. *Expert Opin Pharmacother* 2003; 4: 1659-78.
 76. Perkins SJ, Murphy R, Schmidt U, Williams C. Self-help and guided self-help for eating disorders. *Cochrane Database Syst Rev* 2006; 19, 3: CD004191.
 77. Peterson CB, Mitchell JE. Psychosocial and pharmacological treatment of eating disorders: a review of research findings. *J Clin Psychol* 1999; 55: 685-697.
 78. Petretta M, Bonaduce D, Scalfi L, de Filippo E, Marciano F, Migaux ML, Themistoclakis S, Janniciello A, Contaldo F. Heart rate variability as a measure of autonomic nervous system function in anorexia nervosa. *Clin Cardiol* 1997; 20 (3): 219-224.
 79. Pompili R, Mancinelli J, Ginardi P i wsp. Suicide in anorexia nervosa: a metaanalysis. *Int Eat Dis* 2004; 36 (1): 99-103.
 80. Pope HG Jr, Hudson JI, Jonas JM, Yurgelun-Todd D. Bulimia treated with imipramine; a placebo –controlled, double – blind study. *Am. J Psychiatry* 1983; 140: 554-558.
 81. Pope HG Jr, Hudson JI, Jonas JM, Yurgelun-Todd D. Antidepressant treatment of bulimia: a two-year follow-up study. *J Clin Psychopharmacol* 1985; 5: 320-327.
 82. Pope HG Jr, Hudson JI. Treatment of bulimia with antidepressants. *Psychopharmacology* 1982; 78: 176-179.
 83. Rabe-Jabłońska J (red.). Powikłania somatyczne jadłowstrętu psychicznego. Biblioteka Psychiatrii Polskiej, 2006.
 84. Ramsay R., Ward A, Treasure J i wsp. Compulsory treatment in anorexia nervosa: short-term benefits and long-term mortality. *Br J Psychiatr* 1999; 175: 147-153.
 85. Ratnasuriya RH, Eisler J, Szmukler GJ i wsp. Anorexia nervosa: outcome and prognostic factors after 20 years. *Br J Psychiatry* 1991;158: 495-502.
 86. Ricca V, Mannucci E, Mezzani B, Moretti S i wsp. Fluoxetine and fluvoxamine combined with individual cognitive – beha-

- viour therapy in binge – eating disorders: a one-year follow-up study. *Psychother Psychosom* 2001; 70: 298-306.
87. Russell GFM, Shmuckler GI, Dare C. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. *Arch Gen Psychiatry* 1987; 44: 1047.
 88. Sakka S, Hurst P, Khawaja H. Anorexia nervosa and necrotizing colitis: case report and review of the literature. *Postgrad Med J* 1994; 70 (823): 369-370.
 89. Schmidt U, Tiller J, Hoades, M, Treasure J. Risk factors for developmental of early onset bulimia nervosa. W: *Eating disorders in adolescence* (red.: Steinhausen HC) Walter de Gruyter, Berlin, New York 1995: 83-94.
 90. Steinhausen H-C. Clinical guidelines for anorexia nervosa and bulimia nervosa. *Eur Child and Adolesc Psychiatry* 1997; 6: 121-128.
 91. Steinhausen H-C, Boydjiewa S, Grigoriu-Serbanescu M, Seidel R i wsp. A transcultural outcome study of adolescent eating disorders. *Acta Psychiatr Scand* 2000; 101: 60-66.
 92. Striegel-Moore RH, Franco DL. Epidemiology of binge eating disorder. *Int J Eat Disord* 2003; 34 Suppl: 19-29.
 93. Sullivan PF. Mortality in anorexia nervosa. *Am J Psychiatr* 1995; 152: 1073-1074.
 94. Szmukler GI, Young GP, Lichtenstein M, Andrews JT. A serial study of gastric emptying in anorexia nervosa and bulimia. *Aust NZ J Med* 1990; 20 (3): 220-225.
 95. Śmiech A, Wyszogrodzka- Kucharska A, Rabe-Jabłońska J. Układ kostny w zaburzeniach odżywiania. *Post Psychiatr Neurol* 2003; 12: 79-88.
 96. Telch CF, Agras WS, Linchan MM. Dialectical behaviour therapy for binge eating disorder. *J Consult Clin Psychol* 2001; 69: 1061-1065.
 97. Theander S. Outcome and prognosis in anorexia nervosa and bulimia: Some results of previous investigations compared with those of a Swedish long-term study. *J Psychiatry Res* 1985; 19: 493.
 98. Tiel A. Are psychotropic drugs necessary for the treatment of anorexia nervosa and bulimia nervosa? *Psychother Psychosom Med Psychol* 1997; 47: 332-345.
 99. Tomaszewicz-Libudzić C, Jagielska G, Komender J, Bober-Olesińska K, Retka W. Zagrożające życiu zaburzenia metaboliczne i patofizjologiczne u chorych na jadłowstręt psychiczny. *Psychiatr Pol* 1997; 31 (6): 713-721.
 100. Walsh BT, Devlin MJ. Pharmacotherapy of bulimia nervosa and binge – eating disorder. *Addict Behav* 1995; 20: 757-764.
 101. Wilson GT, Fairburn CG. Cognitive treatments for eating disorders. *J Consult Clin Psychol* 1993; 61: 261- 269.
 102. Yager J, Devlin MJ, Haimi KA, Herzog DB i wsp. Guidelines of treatment patients with eating disorders 2 edition, APA, February 2005.
 103. Yatyura-Tobias JA, Pinto A, Neziroglu F. Anorexia nervosa, diabetes mellitus, and fatty liver. *Int. J. Eat. Disord.* 2001; 30 (3): 350-353.
 104. Zhu AJ, Walsh BT. Pharmacologic treatment of eating disorders. *Can J Psychiatry* 2002; 47: 227-234.